Dickson K, Wu H, Sharma R, Stepien K, Jovanovic A, Chinnadurai R
Medicina (Kaunas). 2024; 60(11).
PMID: 39596918
PMC: 11595874.
DOI: 10.3390/medicina60111733.
Omer S, Nagy N, Pinke B, Meszaros L, Kazsoki A, Zelko R
Pharmaceutics. 2024; 16(8).
PMID: 39204398
PMC: 11360779.
DOI: 10.3390/pharmaceutics16081052.
Bellomo F, Pugliese S, Cairoli S, Krohn P, De Stefanis C, Raso R
J Am Soc Nephrol. 2024; 35(11):1493-1506.
PMID: 38995697
PMC: 11543012.
DOI: 10.1681/ASN.0000000000000439.
Medaer L, David D, Smits M, Levtchenko E, Sampaolesi M, Gijsbers R
Cells. 2024; 13(7.
PMID: 38607085
PMC: 11011962.
DOI: 10.3390/cells13070646.
Stabouli S, Sommer A, Kraft S, Schweer K, Bethe D, Bertholet-Thomas A
Pediatr Nephrol. 2024; 39(10):2861-2874.
PMID: 38517536
PMC: 11349776.
DOI: 10.1007/s00467-024-06345-1.
Gastrointestinal challenges in nephropathic cystinosis: clinical perspectives.
Joseph M, Stein D, Stein A
Pediatr Nephrol. 2024; 39(10):2845-2860.
PMID: 38393360
PMC: 11349842.
DOI: 10.1007/s00467-023-06211-6.
The Clinical Manifestations and Disease Burden of Cystinosis in Saudi Arabia: A Single-Tertiary Center Experience.
Algasem R, Zainy N, Alsabban E, Almojalli H, Raza S, Ali T
Cureus. 2024; 16(1):e52662.
PMID: 38380220
PMC: 10877213.
DOI: 10.7759/cureus.52662.
A Comparative Pharmacokinetic Study for Cysteamine-Containing Eye Drops as an Orphan Topical Therapy in Cystinosis.
Csorba A, Katona G, Budai-Szucs M, Balogh-Weiser D, Molnar P, Maka E
Int J Mol Sci. 2024; 25(3).
PMID: 38338900
PMC: 10855117.
DOI: 10.3390/ijms25031623.
Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom.
Lashilola S, Xu W, Azimpour K, McCarthy M, Carlot S, Game D
BMC Nephrol. 2023; 24(1):351.
PMID: 38031005
PMC: 10688492.
DOI: 10.1186/s12882-023-03392-y.
Worldwide disparities in access to treatment and investigations for nephropathic cystinosis: a 2023 perspective.
Regnier M, Flammier S, Boutaba M, Ndongo A, Servais A, Schaefer F
Pediatr Nephrol. 2023; 39(4):1113-1123.
PMID: 37978055
PMC: 10899370.
DOI: 10.1007/s00467-023-06179-3.
User-friendly and ultra-stable all-inclusive gold tablets for cysteamine detection.
Al-Kassawneh M, Sadiq Z, Jahanshahi-Anbuhi S
RSC Adv. 2023; 13(28):19638-19650.
PMID: 37397283
PMC: 10308203.
DOI: 10.1039/d3ra03073c.
A rare case of a patient with cystinosis and COVID-19 pneumonia with difficult weaning from mechanical ventilation: the "pocus force".
Vetrugno L, Angelini V, Smiraglia S, Saraceni E, di Giannatale P, Maggiore S
J Anesth Analg Crit Care. 2023; 2(1):26.
PMID: 37386678
PMC: 9191537.
DOI: 10.1186/s44158-022-00053-8.
The gene therapy for corneal pathology with novel nonsense cystinosis mouse lines created by CRISPR Gene Editing.
Dong F, Amlal H, Venkatakrishnan J, Zhang J, Fry M, Yuan Y
Ocul Surf. 2023; 29:432-443.
PMID: 37355021
PMC: 10725217.
DOI: 10.1016/j.jtos.2023.06.002.
The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study.
Bjerre A, Aase S, Radtke M, Siva C, Gudmundsdottir H, Forsberg B
Pediatr Nephrol. 2023; 38(11):3671-3679.
PMID: 37219641
PMC: 10514171.
DOI: 10.1007/s00467-023-06005-w.
De novo 11q13.3q13.4 deletion in a patient with Fanconi renotubular syndrome and intellectual disability: Case report and review of literature.
Shen Y, Xu X, Chen J, Wang J, Dong G, Huang K
Front Pediatr. 2023; 11:1097062.
PMID: 37152320
PMC: 10160663.
DOI: 10.3389/fped.2023.1097062.
Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis.
Nemutlu E, Ozaltin F, Yabanoglu-Ciftci S, Gulhan B, Eylem C, Baysal I
Int J Mol Sci. 2023; 24(3).
PMID: 36768921
PMC: 9916752.
DOI: 10.3390/ijms24032603.
A new proof of evidence of cysteamine quantification for therapeutic drug monitoring in patients with cystinosis.
Franzin M, Rossetto S, Ruoso R, Del Savio R, Stocco G, Decorti G
Orphanet J Rare Dis. 2022; 17(1):400.
PMID: 36329442
PMC: 9632017.
DOI: 10.1186/s13023-022-02540-1.
Genistein improves renal disease in a mouse model of nephropathic cystinosis: a comparison study with cysteamine.
De Leo E, Taranta A, Raso R, Polishchuk E, DOria V, Pezzullo M
Hum Mol Genet. 2022; 32(7):1090-1101.
PMID: 36300303
PMC: 10026248.
DOI: 10.1093/hmg/ddac266.
Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients.
Levtchenko E, Servais A, Hulton S, Ariceta G, Emma F, Game D
Clin Kidney J. 2022; 15(9):1675-1684.
PMID: 36003666
PMC: 9394719.
DOI: 10.1093/ckj/sfac099.
Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis.
Hector E, Cairns D, Wall G
Orphanet J Rare Dis. 2022; 17(1):231.
PMID: 35710564
PMC: 9205078.
DOI: 10.1186/s13023-022-02367-w.